These A/Cal DI particles can transmit the antiviral 244 DI virus to other cells in the respiratory tract, and progressively increase the number of cells that are able to resist infection through the

presence of DI RNA. Treatment with DI virus did not adversely affect the clearance of virus infectivity, and DI RNA was cleared from nasal secretions at a similar rate. The role of interferon see more in protection of ferrets from A/Cal was not investigated. Studies in mice showed that active DI virus given intranasally in the absence of infectious virus stimulates production of interferon type I in the lung, and that the UV-inactivated DI virus did not stimulate detectable interferon type I in the lung. However, use of interferon receptor knock-out mice showed that interferon was not required for protection against type A influenza virus (Dimmock et al., 2008), but did protect mice from pneumonia virus of mice and an influenza B virus (Easton et al., 2011 and Scott et al., 2011b). UV-inactivated DI virus did not protect, and thus does not induce interferon type I. Oseltamivir

treatment was also beneficial although it did not cause any significant decrease in weight loss or respiratory disease when compared to the infected animals that AT13387 clinical trial were not given any other treatment. Oseltamivir reduced virus load on day 2, but the virus load in oseltamivir-treated animals was more than 100-fold

greater than the virus control on day 6. This differential appears consistent with a viral rebound observed following the cessation of oseltamivir treatment in people infected with pandemic 2009 virus (Lee et al., 2011). We also examined virus from oseltamivir-treated ferrets on day 6 by sequencing for the H275Y mutation that is associated with resistance to oseltamivir (Ives et al., 2002) but this mutation was not found (unpublished data). The H275Y mutation was also absent from rebound virus in the oseltamivir-treated human cohort (Lee et al., 2011). We surmise that the rebound virus may result from the release of progeny virus that had before been bound to cell receptors because of the inhibition of viral neuraminidase activity by oseltamivir. All Flavopiridol (Alvocidib) ferrets developed A/Cal-specific, serum HI antibody, but there was significantly less in the oseltamivir-treated infected group than in the DI virus treated infected group. In addition to the signs and symptoms described above ferrets were monitored in the morning and the afternoon for loss of appetite, appearance of diarrhoea, and reduction in activity. None of these was seen in any group. We conclude that treatment of ferrets with 244 DI virus ameliorates clinical disease and virus load resulting from infection with pandemic A/California/04/09 (H1N1) more effectively than did treatment with oseltamivir.